Epstein–Barr virus latent membrane protein 1 (LMP1)

Epstein–Barr virus latent membrane protein 1 (LMP1) is an integral membrane protein encoded by EBV and is regarded as the principal EBV oncoprotein. LMP1 functions as a constitutively active pseudo-receptor, mimicking the tumor necrosis factor receptor (TNFR) family—especially CD40—but independently of an extracellular ligand. Structurally, it has a short cytoplasmic N-terminus, six transmembrane domains responsible for spontaneous oligomerization in the membrane, and a long cytoplasmic C-terminus containing activating regions (CTAR1/2/3) essential for interaction with host signaling proteins including TRAFs, TRADD, JAK/STAT, and others. LMP1 constitutively activates several oncogenic signaling pathways (NF-κB, MAPK/JNK, JAK/STAT) leading to enhanced proliferation, survival, and transformation of host cells. It is critical for the development and maintenance of EBV-associated malignancies, including multiple lymphomas and nasopharyngeal carcinoma, and is used as a biomarker in pathology. Although there are currently no drugs approved targeting LMP1 directly, its structure and signaling domains are the subject of active cancer therapeutic research[1][2][3][4][5][6][7].

Other names

Latent membrane protein 1EBV-LMP1LMP-1EBV-associated membrane antigen

Inhibition of LMP1 or downstream signal transduction (NF-κB, JAK/STAT, MAPK pathways); Blocking LMP1 oligomerization or membrane localization